Supports high-risk, high-impact research on HIV and substance use to advance HIV prevention, diagnosis, treatment, and virus suppression among people who use substances or have substance use disorders.
Funder: National Institutes of Health
Due Dates: September 25, 2026 (Application and references) | September 25, 2027 (Application and references) | September 25, 2028 (Final application and references)
Funding Amounts: Up to $700,000/year for established investigators or $375,000/year for early stage investigators, for up to 5 years
Summary: Supports pioneering, high-risk research at the intersection of HIV and substance use, including prevention, diagnosis, treatment, and viral suppression.
Key Information: Research must represent a substantially new direction, not an expansion of an ongoing funded project.
The National Institute on Drug Abuse (NIDA), part of NIH, runs this DP1 program to support exceptionally creative scientists pursuing potentially transformative HIV research in the context of substance use or substance use disorders (SUDs). It funds basic, clinical, translational, and implementation science addressing critical problems at this intersection. Clinical trials are optional.
The program emphasizes creativity and potential impact rather than a particular discipline. Relevant work includes novel HIV prevention strategies, closing gaps in pre-exposure prophylaxis and care, addressing HIV-related comorbidities, and mechanistic research informing treatment and cure. Proposals must align with NIH HIV/AIDS research priorities and explain why substance use matters, how it is addressed, and how outcomes benefit people who use substances or have SUDs.